Stockscreener 앱 받기
12.66
4.28%
0.52
시간 외 거래:
12.77
0.11
+0.87%
전일 마감가:
$12.14
열려 있는:
$12.25
하루 거래량:
64,437
Relative Volume:
0.05
시가총액:
$127.96M
수익:
$88.50M
순이익/손실:
$-35.27M
주가수익비율:
-3.8417
EPS:
-3.2954
순현금흐름:
$-23.70M
1주 성능:
-11.16%
1개월 성능:
-29.19%
6개월 성능:
+70.62%
1년 성능:
+10.66%
1일 변동 폭
$12.25
$13.05
1주일 범위
$12.13
$14.40
52주 변동 폭
$3.436
$20.21
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
12.66 | 122.70M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Aberdeen Group plc Takes $1.78 Million Position in Biodesix, Inc. $BDSX - MarketBeat
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix (NASDAQ: BDSX) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Employees put Biodesix on USA TODAY's Top Workplaces list for a third year - Stock Titan
Rate Hike: Can Biodesix Inc expand into new marketsQuarterly Portfolio Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Biodesix, Inc. (BDSX) stock price, news, quote and history - Yahoo Finance UK
Biodesix Unveils Novel Diagnostic Test at AACR 2026 - National Today
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development - The Manila Times
Biodesix to Showcase Advances in Diagnostic Solutions at AACR Annual Meeting 2026 - Quiver Quantitative
Cancer test developer Biodesix brings 7 studies to AACR meeting - Stock Titan
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year? - qz.com
Energy Moves: Can Biodesix Inc expand into new markets2026 Big Picture & Precise Buy Zone Identification - baoquankhu1.vn
BDSX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Biodesix (BDSX) chair adds 1,361 shares through RSU exercise - Stock Titan
Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street analysts see an 86.45% upside in Biodesix (BDSX): Can the stock really move this high? - MSN
AI Stocks: Can Biodesix Inc expand into new marketsMarket Growth Review & Technical Entry and Exit Tips - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 19.4% in March - MarketBeat
Weekly Earnings: What is the dividend yield of Biodesix IncQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
$Biodesix (BDSX.US)$ I am out - moomoo.com
Is Biodesix (BDSX) stock outpacing its medical peers this year? - MSN
If You Invested $1,000 in BIODESIX INC (BDSX) - Stock Titan
Biodesix publishes lung nodule biomarker validation study By Investing.com - Investing.com Australia
Biodesix, Inc.Common Stock (NQ: BDSX - The Chronicle-Journal
Biodesix publishes lung nodule biomarker validation study on 1,100 patients - Investing.com
Biodesix publishes lung nodule biomarker validation study - Investing.com
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis - The Manila Times
Biodesix Publishes Largest Lung Nodule Biomarker Study, Validating Nodify CDT® Test for Lung Cancer Risk Assessment - Quiver Quantitative
Study of 1,100 patients backs blood test for earlier lung cancer diagnosis - Stock Titan
Is Biodesix (BDSX) Shares Performing Better Than Other Medical Stocks This Year? - Bitget
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Yahoo Finance
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Treasury Yields: Can Biodesix Inc navigate macro headwinds2026 Pullbacks & Comprehensive Market Scan Insights - baoquankhu1.vn
Biodesix, Inc. (BDSX) reports Q4 loss, beats revenue estimates - MSN
Wall Street analysts think Biodesix (BDSX) could surge 111.62%: Read this before placing a bet - MSN
Decliners Report: Is Biodesix Inc benefiting from innovation trends2026 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Cannell & Spears LLC Sells 195,326 Shares of Biodesix, Inc. $BDSX - MarketBeat
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference - MarketBeat
Recap Report: What is the dividend yield of Biodesix IncNew Guidance & Accurate Trade Setup Notifications - baoquankhu1.vn
BDSX SEC FilingsBIODESIX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Biodesix Receives 'Moderate Buy' Rating from Analysts - National Today
Biodesix at Barclays Conference: Strategic Growth in Lung Cancer Diagnostics - Investing.com Canada
Biodesix Earnings Call Signals Growth With Caveats - TipRanks
Setup Watch: Is Biodesix Inc in a consolidation phase2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference - MarketBeat
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.41%
1.61%
자본화:
|
볼륨(24시간):